Genencell Co. Ltd.
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Private
- Established
- 2016-08-26
- Employees
- -
- Market Cap
- -
- Website
- http://www.genencell.co.kr
Efficacy and Safety of ES16001 in Patients With COVID-19
Phase 2
Recruiting
- Conditions
- COVID-19
- Interventions
- Drug: ES16001 40 mgDrug: ES16001 80 mgDrug: ES16001 160 mgDrug: Placebo
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Genencell Co. Ltd.
- Target Recruit Count
- 706
- Registration Number
- NCT05525182
- Locations
- π°π·
Kyung Hee University Medical Center, Seoul, Korea, Republic of
π°π·Eunpyeong, St.Mary's Hospital, Seoul, Korea, Republic of
π°π·Soon Chun Hyang University Hospital, Bucheon, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath